Q3 2021 Financial Presentation2021-11-04 The Executive Managment in Ascelia Pharma presents a business update and the quarterly results InvestorGenväg till IR & Media IR & Media Key downloads QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completedCorrection: Ascelia Pharma publishes annual report for 2022Ascelia Pharma publishes annual report for 2022QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023.QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission
